Summary
The metabolism of methaqualone to the glucuronides of 5 C-monohydroxy metabolites and to the N-oxide has been studied in 2 groups of healthy young adults phenotyped as extensive and poor metabolisers of debrisoquine. No significant interphenotype differences were observed with respect to the excretion of any of the 6 metabolites. It is probable that the genetic regulation of the pathways leading to these metabolites is at a locus other than that which is responsible for the regulation of the oxidation of debrisoquine, guanoxan, phenacetin, phenytoin and sparteine.
Similar content being viewed by others
References
Alván G, Lindgren J, Bogentoft G, Ericsson Ö (1973) Plasma kinetics of methaqualone in man after single oral doses. Eur J Clin Pharmacol 6:187–190
Burnett D, Reynolds CN, Wilson K, Francis JR (1976) Urinary excretion of C-hydroxy derivatives of methaqualone in man. Xenobiotica 6:125–134
Eichelbaum M, Spannbrucker N, Dingler HJ (1978) A probably genetic defect of the metabolism of sparteine. In: Gorrod JW (ed) Biological oxidation of nitrogen. Elsevier/North Holland, Amsterdam, pp 113–118
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183–187
Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in the British white population. J Med Genet 17:102–105
Gorrod J (1978) The current status of the pKa concept on the differentiation of enzymic N-oxidation. In: Gorrod JW (ed) Biological oxidation of nitrogen, Elsevier/North Holland, Amsterdam, pp 201–210
Idle JR, Oates NS, Shah RR, Smith RL (1981) Is there a genetic predisposition to phenformin-induced lactic acidosis? Br J Clin Pharmacol 11:418–419
Inaba T, Otton SV, Kalow W (1980) Deficient metabolism of debrisoquine and sparteine. Clin Pharmacol Ther 27:547–549
Irvine RE, Grove J, Toseland PA, Trounce JR (1974) The effect of age on the hydroxylation of amylobarbitone sodium in man. Br J Clin Pharmacol 1:41–43
Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) The polymorphic hydroxylation of debrisoquine in man. Lancet 2:584–586
Manowitz P, Shull CM (1976) Methaqualone metabolism by rat liver microsomes. Res Comm Chem Pathol Pharmacol 13:27–39
McReynolds JH, Heck H, Anabar M (1975) Determination of picomole quantities of methaqualone and 6-hydroxymethaqualone in urine. Biomed Mass Spectrom 2:299–303
Reynolds CN, Wilson K, Burnett D (1976) Urinary excretion of methaqualone-N-oxide in man. Xenobiotica 6:113–124
Reynolds CN, Wilson K, Burnett D (1978) Metabolism of methaqualone in geriatric patients. Eur J Clin Pharmacol 13:285–290
Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL (1978) Polymorphism of carbon oxidation and clinical implications. Br Med J 2:655–657
Sloan TP, Idle JR, Smith RL (1981) Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther 29:493–497
Smyth RD, Lee JK, Polk A, Chemburkar PB, Savacool AM (1973) Bioavailability of methaqualone. J Clin Pharmacol 13:391–400
Wakile LA, Sloan TP, Idle JR, Smith RL (1979) Genetic evidence for the involvement of different oxidative mechanisms in drug oxidation. J Pharm Pharmacol 31:350–354
Wilson K, Reynolds CN, Burnett D (1978) Inter- and intra-individual variation in the metabolism of methaqualone in man after a single oral dose. Eur J Clin Pharmacol 13:291–297
Ziegler DM (1980) Microsomal flavin-containing monoxygenase: oxygenation of nucleophilic nitrogen and sulphur compounds. In: Jakoby WB (ed) Enzymic basis of detoxication. Academic Press, New York, pp 201–227
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oram, M., Wilson, K., Burnett, D. et al. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 23, 147–150 (1982). https://doi.org/10.1007/BF00545969
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00545969